In a new report, ‘Proactive Planning to Navigate Clinical Research Staffing Trends in 2025’, Advanced Clinical looks at hiring trends in 2024, providing valuable insights for navigating cli
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.